



FOR IMMEDIATE RELEASE

May 31, 2007

Contact: Larry Lapila

Breckenridge Pharmaceutical signs Letter of Intent for long-term profit-sharing agreement with Orbus Pharma

Boca Raton, Florida— Breckenridge announced today that it has signed a Letter of Intent with Orbus Pharma (Markham, Ontario) to an exclusive long-term profit-sharing agreement to market Metoprolol Succinate Extended-Release Tablets in the United States.

Under terms of the LOI, Orbus will develop and submit an Abbreviated New Drug Application (“ANDA”) to the U.S. Food and Drug Administration (“FDA”) for metoprolol succinate extended-release tablets. Breckenridge will contribute its experience within the FDA regulatory framework, particularly relating to the ANDA approval process. Upon approval by the FDA, Orbus will manufacture and Breckenridge will market and distribute the product on an exclusive basis in the United States.

Metoprolol Succinate Extended-Release tablets is a once a day beta blocker that can be used alone or in combination with other medications to treat high blood pressure. It is also used to prevent angina and, in combination with other medications, to treat heart failure. The product is a generic form of Astra Zeneca’s branded product, Toprol XL®¹, which had annual sales in the United States of approximately \$1.7 billion in 2006.

About Breckenridge:

Breckenridge Pharmaceutical is a privately-held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of ValuBrand™ and Generic prescription products in many therapeutic categories. Breckenridge currently markets 9 ANDA products and has over a dozen in development. The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets over 100 products, more than 150 sku’s, in a variety of dosage forms including: Tablets, Capsules, Soft Gel Capsules, Liquids, Suspensions and Topical preparations. www.bpirx.com

About Orbus:

Orbus, headquartered in Markham, Ontario and listed on the Toronto Stock Exchange under the symbol ORB, pursues an integrated global strategy of: (1) generic drug development, using proprietary delivery systems for certain products; (2) product out-licensing; and (3) pharmaceutical supply agreement manufacturing. For more information please visit www.orbus.ca

For Further Information, please contact:

Breckenridge Pharmaceutical

Larry Lapila, Vice President Business Development

TEL: 860-828-8140 FAX: 860-828-8142

e-Mail: llapila@bpirx.com

Forward looking statements

Certain statements in this disclosure are “forward-looking statements”, which reflect management’s expectations regarding the Company’s future growth, results of operations, performance and business prospects and opportunities. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. Many factors could cause results to differ materially from the results discussed in the forward-looking statements, including risks related to dependence on key suppliers, economic conditions, competition, regulatory change, foreign exchange rates, and interest rates, among others. Although the forward-looking statements are based on what management believes to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with these forward-looking statements.

¹ Toprol-XL is a registered trademark of the AstraZeneca group.